» Articles » PMID: 16105965

Central Fat Excess in Polycystic Ovary Syndrome: Relation to Low-grade Inflammation and Insulin Resistance

Overview
Specialty Endocrinology
Date 2005 Aug 18
PMID 16105965
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: It is controversial whether the polycystic ovary syndrome (PCOS) per se increases low-grade chronic inflammation and whether this relates to central fat excess. In addition, the association between circulating sex hormones and body fat distribution in premenopausal women is debated.

Methods: Blood was drawn from 20 patients with PCOS and compared with 15 controls, matched for body mass index and age. Regional fat distribution was assessed using dual x-ray absorptiometry.

Results: Compared with controls, patients with PCOS had a higher trunk to extremity fat ratio (T/E fat), were more insulin resistant (higher homeostasis model assessment of insulin resistance and lower SHBG concentrations), and had higher levels of highly sensitive C-reactive protein, TNF-alpha, procalcitonin, and white blood cell count (all P < or = 0.04), even after adjusting for total body fat. However, additional adjusting for T/E fat eliminated or attenuated the effect of PCOS status on estimates of insulin resistance, on inflammatory mediators, and on white blood cell count but not on circulating sex hormones. Independently of each other, total body fat as well as T/E fat correlated with estimates of insulin resistance and most inflammatory mediators (P < or = 0.04). However, the correlations between T/E fat and circulating sex hormones (P < or = 0.02) were greatly reduced after adjustment for the presence of PCOS.

Conclusion: The increase in low-grade chronic inflammation and in insulin resistance in women with PCOS is primarily associated with increased central fat excess rather than PCOS status per se. Procalcitonin represents a novel marker of the inflammatory activity of body fat and of PCOS.

Citing Articles

Visceral adipose tissue, epicardial fat, and hepatic steatosis in polycystic ovary syndrome: a study of ectopic fat stores and metabolic dysfunction.

de Melo Cavalcante R, Leao L, Tavares A, Lopes K, Terra C, Salgado A Endocrine. 2024; 87(2):866-874.

PMID: 39425841 DOI: 10.1007/s12020-024-04077-8.


Effects of interleukin-1 receptor antagonism in women with polycystic ovary syndrome-the FertIL trial.

Walchli-Popovic M, Monnerat S, Taylor A, Gilligan L, Schiffer L, Arlt W Front Endocrinol (Lausanne). 2024; 15:1435698.

PMID: 39324125 PMC: 11423739. DOI: 10.3389/fendo.2024.1435698.


The Impact of Diet-Induced Weight Loss on Inflammatory Status and Hyperandrogenism in Women with Polycystic Ovarian Syndrome (PCOS)-A Systematic Review and Meta-Analysis.

Alenezi S, Elkmeshi N, Alanazi A, Alanazi S, Khan R, Amer S J Clin Med. 2024; 13(16).

PMID: 39201076 PMC: 11355208. DOI: 10.3390/jcm13164934.


Microvesicle-associated and circulating microRNAs in diabetic dyslipidemia: miR-218, miR-132, miR-143, and miR-21, miR-122, miR-155 have biomarker potential.

Nemecz M, Stefan D, Comarita I, Constantin A, Tanko G, Guja C Cardiovasc Diabetol. 2023; 22(1):260.

PMID: 37749569 PMC: 10521428. DOI: 10.1186/s12933-023-01988-0.


Abdominal Obesity in Women with Polycystic Ovary Syndrome and Its Relationship with Diet, Physical Activity and Insulin Resistance: A Pilot Study.

Jurczewska J, Ostrowska J, Chelchowska M, Panczyk M, Rudnicka E, Kucharski M Nutrients. 2023; 15(16).

PMID: 37630842 PMC: 10459970. DOI: 10.3390/nu15163652.